-
Description
Highly Sensitive; Includes Viral Neuraminidase control
-
Summary
• Detection method- fluorescence (Ex/Em = 368/460 nm) • Application- • Rapid assessment of neuraminidase activity in influenza virus isolates • Characterization of neuraminidase inhibitor susceptibility of known or newly emergent influenza strains • High-throughput screening of novel neuraminidase inhibitor antiviral drugs
-
Detection Method
Fluorescence (Ex/Em = 368/460 nm)
-
Species Reactivity
Viral Neuraminidase
-
Applications
• Rapid assessment of neuraminidase activity in influenza virus isolates • Characterization of neuraminidase inhibitor susceptibility of known or newly emergent influenza strains • High-throughput screening of novel neuraminidase inhibitor antiviral drugs
-
Sample Type
• Influenza virus (type A or B, from any host species) isolates (propagated from embryonated chicken eggs or cultured MDCK cells) • Purified or recombinant neuraminidase enzyme preparations
-
Features Benefits
• Simple, rapid & convenient • The assay may also be used for screening of novel neuraminidase inhibitors against known drug-resistant influenza strains.
-
Storage Conditions
-20°C
-
Shipping Conditions
gel pack
-
Shelf life
12 months
-
Background
Neuraminidase (EC 3.2.1.18) is a tetrameric Ca2+-dependent sialidase enzyme that cleaves α-glycosidic linkages of terminal sialic acid residues from the oligosaccharide chains of glycoproteins. Neuraminidase-family enzymes are present in most lifeforms, from bacteria to humans, and are also encoded by several viral genomes, including influenza viruses. Influenza neuraminidase plays a critical role in replication and transmission of the virus by preventing self-aggregation of replicating progeny viral particles and enabling release of active influenza virions from infected host cells. Neuraminidase inhibitors, which competitively block the enzyme-mediated release of newly synthesized viral particles, are widely used as anti-influenza drugs. Rapid mutation of viral neuraminidase can yield new influenza strains that are more pathogenic and also engender resistance to existing neuraminidase inhibitors. Hence, monitoring of neuraminidase activity and inhibitor susceptibility in influenza field isolates collected worldwide is integral to identifying new pandemic influenza strains and guiding public health strategies to control seasonal influenza epidemics. BioVision’s Influenza Neuraminidase Activity/Inhibitor Susceptibility Assay Kit enables rapid measurement of viral neuraminidase activity, utilizing a fluorogenic substrate that is converted into a stable, highly fluorescent product (Ex/Em = 368/460 nm). The assay allows for high-throughput functional screening of baseline neuraminidase activity and inhibitor susceptibility patterns in influenza virus isolates in order to evaluate the possible emergence of new inhibitor-resistant strains. A straightforward, standardized protocol consistent with the latest CDC and WHO research guidelines ensures reproducible neuraminidase inhibitor IC50 data for influenza antiviral susceptibility surveillance. The assay may also be used for screening of novel neuraminidase inhibitors against known drug-resistant influenza strains. The kit includes sufficient reagents to perform at least 1000 reactions (ten assay plates) in a 96-well plate format
-
-
Test
Biovision supplies other types of Assays as 1.
-
Additional description
Influenza A and B H1N1 H3N2 Hemagglutinin-nucleoprotein recombinant proteins, peptides and antibodies detect a virus commonly known as "the flu". Influenza is an infectious disease caused by an influenza virus. Symptoms can be mild to severe. The most common symptoms include a high fever, runny nose, sore throat, muscle pains, headache, coughing, and feeling tired. These symptoms typically begin two days after exposure to the virus and most last less than a week. The cough, however, may last for more than two weeks. In children, there may be nausea and vomiting, but these are not common in adults. Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.
